Project Grant DP2CA301078
Award Date 9/1/24
Completion Date 8/31/27
Dollars Obligated $1.6M
Funding Federal Agency
Awarding Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Philadelphia, PA 19104, USA
Similar Awards
- This federal Project Grant award of $1,399,500.00 from the National Institutes of Health (NIH) under the Trans-NIH Research Support program (CFDA 93.310) supports a research initiative titled "Time-Lapse Epigenome Profiling in Support of Next Generation Cellular Reprogramming". The project, awarded to The Washington University, aims to observe epigenetic factors that influence the efficiency of cellular reprogramming - a process of converting one cell type into another, such as...
- This federal Project Grant award from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) provides $712,000.00 to The Children's Hospital of Philadelphia Research Institute to develop a GPC2 CAR T cell-amplifying extracellular vesicle vaccine. The award period runs from September 1, 2025 to August 31, 2027. As a leading pediatric research institution, The Children's Hospital of Philadelphia has a strong track record of securing federal grants to...
- The New York University (NYU) School of Medicine was awarded a $1,525,500 Project Grant by the National Institutes of Health (NIH) Office of the Director under the Trans-NIH Research Support program (CFDA 93.310). The grant funding, which runs from September 1, 2024 to August 31, 2027, supports the development of new technologies to address two major bottlenecks in the chimeric antigen receptor (CAR) T cell therapy development process: identifying tumor-specific antigens and engineering...
- This Project Grant award from the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) program will provide $934,501 to The Children's Hospital of Philadelphia Research Institute to develop peptide-centric chimeric antigen receptor (CAR) therapies for neurofibromatosis type 1 (NF1)-associated malignant peripheral nerve sheath tumors (MPNSTs). The award began on September 1, 2025 and is scheduled for completion by August 31, 2028. The research aims to advance...
- This federal Project Grant award of $445,000.00 was provided by the National Institute of General Medical Sciences (NIGMS) under the Biomedical Research and Research Training program (CFDA 93.859). The central objective of this 5-year project, starting on June 1, 2025, is to leverage long-read RNA sequencing to elucidate the complexity of the mammalian transcriptome and advance genomic medicine. The project aims to overcome key technological hurdles in long-read RNA sequencing and demonstrate...
- This Project Grant award of $298,530 from the National Institute of General Medical Sciences (NIGMS), under the Biomedical Research and Research Training program (CFDA 93.859), supports the development of self-delivering epigenetic editor therapeutics. The project aims to eliminate the need for transgene delivery by expressing the epigenetic editors as recombinant, self-delivering proteins that can be spontaneously taken up by cells and transported to the nucleus to induce targeted demethylation...
- This $462,000 Project Grant award from the National Institute of General Medical Sciences (NIGMS), under the Biomedical Research and Research Training program (CFDA 93.859), supports research to establish the epigenetic mechanisms that govern embryonic stem cell (ESC) biology. The research aims to define how ESC gene expression programs and biology are regulated by DNA methylation and the TET family of DNA demethylases. Key objectives include: Dissecting the molecular and biological requirements...
- This $470,759 Project Grant was awarded by the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395) to Seattle Children's Hospital, doing business as Seattle Children's Research Institute, to develop a novel CAR T-cell therapy for patients with hepatocellular carcinoma (liver cancer). The project aims to prevent CAR T-cell exhaustion, a key barrier to effective CAR T-cell therapy in solid tumors, by leveraging the researchers' "PA-Regulator"...
- The federal Project Grant award from the National Human Genome Research Institute (NHGRI) under the Human Genome Research program (CFDA 93.172) provides $126,830.00 in funding from February 1, 2025 to January 31, 2027 to The Children's Hospital Corporation, doing business as Boston Children's Hospital. The award will support the development of a somatic mutation-resolved lineage tracing system to reconstruct single-cell genealogical trees and detect associated somatic mutations and epigenetic...
- This federal Project Grant award of $222,500.00 was provided by the National Institutes of Health (NIH) Office of the Director under the Research Infrastructure Programs (CFDA 93.351) to The Children's Hospital Corporation (doing business as Boston Children's Hospital) on May 15, 2025. The funding supports the development of a modular system for CRISPR-based genome and epigenome editing in mice. This includes creating mouse lines that express core CRISPR components (dCas9, nCas9) with protein...